The global methicillin-resistant staphylococcus aureus (MRSA) drugs market is expected to grow at a significant CAGR during the forecast period (2021-2027).  Staphylococcus aureus is a bacterium that can be found on healthy people's nose or skin. MRSA, or methicillin-resistant staphylococcus aureus, is a kind of staphylococcus aureus resistant to methicillin, a beta-lactam antibiotic. Methicillin is ineffective against MRSA strains. MRSA infects around 1% of the population who have staphylococcus aureus on their nose or skin. The infection affects the skin and tissues and spreads through direct skin-to-skin contact. 

MRSA is spread in two out of every 100 people, according to the Centers for Disease Control and Prevention (CDC). In 2020, the number of people who were diagnosed with methicillin-resistant Staphylococcus aureus (MRSA) for the first time was significantly lower than in prior years. 2,883 cases were reported in 2020, compared to 3,657 cases in 2019, 3,669 cases in 2018, 3,579 cases in 2017, and 3,550 cases in 2016. Patients staying in long-term health care institutions for an extended period of time are a crucial component in the outbreak of MRSA infections. According to the Healthcare Cost & Utilization Project (HCUP), a collection of healthcare databases in the US, hospitalized patients are more likely than non-hospitalized patients who died from MRSA infections (4.7% vs. 2.1% respectively). 

Improved detection of antibiotic-resistant bacterium strains utilizing technologically sophisticated diagnostic methods, as well as an increase in antibiotic use across the globe, are likely to propel the growth of the global MRSA antibiotic preparations market. Teixobactin, according to University of Melbourne experts, is effective against MRSA. These findings are anticipated to pave the way for the development of antibacterial medications to treat Gram-positive infections with thick cell walls that are multidrug-resistant. This will support accelerating the market growth.

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Drug Class 

o By Route of Administration 

o By Distribution Channel 

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape:  Pfizer Inc., Merck & Co. Inc, and AbbVie Inc. among others. 

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global MRSA Drugs Market Report by Segment

By Drug Class  

• Lipopeptide
• Oxazolidinone
• Tetracycline
• Cephalosporin
• Lipoglycopeptide
• Others

By Route of Administration 

•  Oral 
• Parenteral

By Distribution Channel 

• Online Pharmacy
• Hospital Pharmacy
• Retail Pharmacy

Global MRSA Drugs Market by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa